SG11201809931YA - 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers - Google Patents
2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancersInfo
- Publication number
- SG11201809931YA SG11201809931YA SG11201809931YA SG11201809931YA SG11201809931YA SG 11201809931Y A SG11201809931Y A SG 11201809931YA SG 11201809931Y A SG11201809931Y A SG 11201809931YA SG 11201809931Y A SG11201809931Y A SG 11201809931YA SG 11201809931Y A SG11201809931Y A SG 11201809931YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- brain
- treatment
- michael
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number 0 (43) International Publication Date .....0\"\" WO 2017/197062 Al 16 November 2017 (16.11.2017) WIPO I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: (74) Agent: LIU, Wansheng, Jerry et al.; Fox Rothschild A61K 31/506 (2006.01) C07D 403/04 (2006.01) LLP, 997 Lenox Drive, Building 3, Lawrenceville, NJ 08648-2311 (US). International Application Number: PCT/US2017/032066 (81) Designated States (unless otherwise indicated, for every International Filing Date: kind of national protection available): AE, AG, AL, AM, 11 May 2017 (11.05.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, Publication Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, Priority Data: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 62/334,830 11 May 2016 (11.05.2016) US PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, Applicant: BETA PHARMA, INC. [US/US]; 1000 N. TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. West St., Suite 1200, Wilmington, DE 19801 (US). (84) Designated States (unless otherwise indicated, for every Inventors: GRECO, Michael, Nicholas; 1634 Clearbrook kind of regional protection available): ARIPO (BW, GH, Road, Lansdale, PA 19446 (US). COSTANZO, Michael, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, John; 14 Breckenridge Drive, Warminster, PA 18974 (US). UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, GREEN, Michael, Alan; 1184 Dewalt Drive, Easton, PA TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 18040 (US). PENG, Jirong; 11019 North Kensington Dr., EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Mequon, WI 53097 (US). WILDE, Victoria, Lynn; 50 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Pine Street, Montclair, NJ 07042 (US). ZHANG, Don; 9 Kensington Court, Princeton, NJ 08540 (US). — = Title: 2-ANILINOPYRIMIDINE DERIVATIVES AS THERAPEUTIC AGENTS FOR TREATMENT OF BRAIN CANCERS Brain Bioiuminostence Sigrud Group compari tc with Std. Error , = (54) = = _ = — = = = = = = = = 0 10 1 2=4 RcE 3$ .Tii.rnor Mitil(I rit WU Figure 1. Brain Tumor BL1 Signal Group comparisons. : Methods of using substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, or corn- for the treatment of brain cancers, in particular EGFR-mediated metastatic brain cancer, are disclosed. © positions, 11 N V::+ © IN C:r 11 IN 1-1 (57) el C [Continued on next page] WO 2017/197062 Al MIDEDIMOMMIDIRMEMOMOIHEIMIHIMEDIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662334830P | 2016-05-11 | 2016-05-11 | |
| PCT/US2017/032066 WO2017197062A1 (en) | 2016-05-11 | 2017-05-11 | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809931YA true SG11201809931YA (en) | 2018-12-28 |
Family
ID=60267544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809931YA SG11201809931YA (en) | 2016-05-11 | 2017-05-11 | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11052086B2 (en) |
| EP (1) | EP3454860A4 (en) |
| JP (1) | JP6908287B2 (en) |
| KR (1) | KR20190006991A (en) |
| CN (1) | CN109715164A (en) |
| AU (1) | AU2017264839B2 (en) |
| BR (1) | BR112018072887A2 (en) |
| CA (1) | CA3023228A1 (en) |
| CO (1) | CO2018012061A2 (en) |
| EA (1) | EA201892311A1 (en) |
| IL (1) | IL262801A (en) |
| MX (1) | MX2018013602A (en) |
| PH (1) | PH12018502360A1 (en) |
| SG (1) | SG11201809931YA (en) |
| TW (1) | TW201740951A (en) |
| WO (1) | WO2017197062A1 (en) |
| ZA (1) | ZA201807353B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3399968B8 (en) | 2016-01-07 | 2021-12-01 | Xuanzhu Biopharmaceutical Co., Ltd. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| JP6928964B2 (en) | 2016-06-17 | 2021-09-01 | ベータ ファーマ，インコーポレイテッド | N- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5-((4- (1-methyl-1H-indole-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide Pharmaceutical salts and their crystalline form |
| CN110799191B (en) | 2017-06-16 | 2023-05-26 | 贝塔制药有限公司 | Pharmaceutical formulations of N- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide and salts thereof |
| CN111100117B (en) * | 2019-12-18 | 2021-02-19 | 上海倍而达药业有限公司 | Crystal form A of aminopyrimidine compound mesylate and preparation method and application thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7078409B2 (en) * | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
| EP2137535B1 (en) * | 2007-04-13 | 2015-06-03 | Dana-Farber Cancer Institute, Inc. | Receptor tyrosine kinase profiling |
| TWI619713B (en) * | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | Compounds and methods for kinase modulation, and indications therefor |
| EA201391626A1 (en) * | 2011-05-04 | 2014-03-31 | Ариад Фармасьютикалз, Инк. | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-STIMULATED CANCER TYPES |
| SG10201402860QA (en) | 2011-07-27 | 2014-08-28 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| WO2013106460A2 (en) | 2012-01-09 | 2013-07-18 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating malignant astrocytomas |
| GEP20197011B (en) | 2014-06-19 | 2019-08-12 | Ariad Pharma Inc | Heteroaryl compounds for kinase inhibition |
| WO2016029839A1 (en) | 2014-08-25 | 2016-03-03 | 四川海思科制药有限公司 | (substituted phenyl) (substituted pyrimidine) amino derivative, preparation method therefor, and medication use |
| CN105461695B (en) | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | Pyrimidine or pyrrolotriazine derivatives and its production and use |
| CN105085489B (en) * | 2014-11-05 | 2019-03-01 | 益方生物科技（上海）有限公司 | Pyrimidine or pyridine compounds and their, preparation method and medical usage |
| WO2016094821A2 (en) | 2014-12-11 | 2016-06-16 | Beta Pharma, Inc. | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
-
2017
- 2017-05-11 US US16/300,949 patent/US11052086B2/en active Active
- 2017-05-11 EP EP17796819.5A patent/EP3454860A4/en active Pending
- 2017-05-11 AU AU2017264839A patent/AU2017264839B2/en active Active
- 2017-05-11 MX MX2018013602A patent/MX2018013602A/en unknown
- 2017-05-11 WO PCT/US2017/032066 patent/WO2017197062A1/en unknown
- 2017-05-11 TW TW106115602A patent/TW201740951A/en unknown
- 2017-05-11 CN CN201780036188.7A patent/CN109715164A/en active Pending
- 2017-05-11 SG SG11201809931YA patent/SG11201809931YA/en unknown
- 2017-05-11 BR BR112018072887-0A patent/BR112018072887A2/en not_active Application Discontinuation
- 2017-05-11 KR KR1020187035380A patent/KR20190006991A/en not_active Application Discontinuation
- 2017-05-11 CA CA3023228A patent/CA3023228A1/en not_active Abandoned
- 2017-05-11 EA EA201892311A patent/EA201892311A1/en unknown
- 2017-05-11 JP JP2018559217A patent/JP6908287B2/en active Active
-
2018
- 2018-11-02 ZA ZA2018/07353A patent/ZA201807353B/en unknown
- 2018-11-05 IL IL262801A patent/IL262801A/en unknown
- 2018-11-07 CO CONC2018/0012061A patent/CO2018012061A2/en unknown
- 2018-11-09 PH PH12018502360A patent/PH12018502360A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL262801A (en) | 2018-12-31 |
| WO2017197062A1 (en) | 2017-11-16 |
| PH12018502360A1 (en) | 2019-03-25 |
| BR112018072887A2 (en) | 2019-03-06 |
| KR20190006991A (en) | 2019-01-21 |
| MX2018013602A (en) | 2019-08-22 |
| US11052086B2 (en) | 2021-07-06 |
| JP6908287B2 (en) | 2021-07-21 |
| EP3454860A4 (en) | 2020-01-15 |
| CO2018012061A2 (en) | 2018-11-22 |
| EP3454860A1 (en) | 2019-03-20 |
| ZA201807353B (en) | 2019-08-28 |
| US20190365755A1 (en) | 2019-12-05 |
| JP2019514996A (en) | 2019-06-06 |
| TW201740951A (en) | 2017-12-01 |
| AU2017264839A1 (en) | 2018-11-22 |
| CA3023228A1 (en) | 2017-11-16 |
| EA201892311A1 (en) | 2019-06-28 |
| CN109715164A (en) | 2019-05-03 |
| AU2017264839B2 (en) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201806307YA (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201809931YA (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases |